Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 100

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 100
---
, except share and per share data)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)RevenuesNet product sales$168,542 $170,302 $468,525 $471,301 Collaboration revenue (ZURZUVAE)20,164 — 20,164 — Royalty, licensing and other revenues3,397 5,387 18,691 16,357 Total revenues192,103 175,689 507,380 487,658 Costs and expensesCost of revenues(a)18,965 17,583 51,555 51,808 Research and development29,366 29,036 78,408 80,149 Selling, general and administrative179,678 69,753 363,173 242,173 Amortization of intangible assets24,325 19,488 64,930 59,733 Contingent consideration loss (gain)— (1,016)7,660 (6,466)Total costs and expenses252,334 134,844 565,726 427,397 Operating earnings (loss)(60,231)40,845 (58,346)60,261 Other income (expense)Interest and other income, net2,277 4,098 11,230 11,227 Total other income (expense), net2,277 4,098 11,230 11,227 Earnings (loss) before income taxes(57,954)44,943 (47,116)71,488 Income tax expense (benefit)(12,837)6,446 (12,671)12,951 Net earnings (loss)$(45,117)$38,497 $(34,445)$58,537 Earnings (Loss) per shareBasic$(0.80)$0.70 $(0.61)$1.06 Diluted$(0.80)$0.69 $(0.61)$1.05 Weighted average shares outstandingBasic56,552,741 55,149,760 56,133,918 54,977,199 Diluted56,552,741 56,016,350 56,133,918 55,791,185 _____________________________

(a)